Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (130 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-06-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerreceivingtransplantchemotherapykidney
  Phrases that lowered it: mmhgallergicalcoholagedsafety
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 21 (lowers risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 59.6% (lowers risk) · Drug's FDA history
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 16.3% (lowers risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 74 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 5 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease NCT05432167 · started 2022 · scored riskier than 39% of active trials completed
• A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease NCT04736628 · started 2021 · scored riskier than 22% of active trials completed
• A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses NCT05491642 · started 2022 · scored riskier than 43% of active trials completed
• Sodium Nitrite to Treat Arterial Aging NCT02022670 · started 2011 · scored riskier than 21% of active trials completed
• Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria NCT00625820 · started 2008 · scored riskier than 34% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.